INTERVIEW: Janssen India Boss On Sirturo Pricing And Real World Evidence
This article was originally published in PharmAsia News
India has introduced Janssen's Sirturo, a poster child in the war against multidrug-resistant tuberculosis, through its Revised National Tuberculosis Control Program.
You may also be interested in...
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.
Anil Koul, part of the Johnson & Johnson team that discovered and developed TB drug Sirturo, is currently on a sabbatical to head up IMTECH, an Indian R&D institute. Koul shares with Scrip the ups and downs of Sirturo's development journey and outlines what he hopes to achieve at IMTECH.
South East Asia is gearing for additional momentum in the fight against TB, a disease that caused nearly 800,000 deaths in the region in 2015. Increased budgetary outlays, a regional “Innovation to Implementation” fund and the need for high impact interventions were among the key issues brought up at a recent ministerial meeting in India.